ml5001239_si_001.pdf (231.88 kB)

Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain

Download (231.88 kB)
journal contribution
posted on 12.06.2014, 00:00 by Harry R. Chobanian, Yan Guo, Ping Liu, Marc D. Chioda, Selena Fung, Thomas J. Lanza, Linda Chang, Raman K. Bakshi, James P. Dellureficio, Qingmei Hong, Mark McLaughlin, Kevin M. Belyk, Shane W. Krska, Amanda K. Makarewicz, Elliot J. Martel, Joseph F. Leone, Lisa Frey, Bindhu Karanam, Maria Madeira, Raul Alvaro, Joyce Shuman, Gino Salituro, Jenna L. Terebetski, Nina Jochnowitz, Shruti Mistry, Erin McGowan, Richard Hajdu, Mark Rosenbach, Catherine Abbadie, Jessica P. Alexander, Lin-Lin Shiao, Kathleen M. Sullivan, Ravi P. Nargund, Matthew J. Wyvratt, Linus S. Lin, Robert J. DeVita
We report herein the identification of MK-4409, a potent and selective fatty acid amide hydrolase (FAAH) inhibitor. Starting from a high throughput screening (HTS) hit, medicinal chemistry efforts focused on optimizing of FAAH inhibition in vitro potency, improving the pharmacokinetic (PK) profile, and increasing in vivo efficacy in rodent inflammatory and neuropathic pain assays.

History

Exports